Please login to the form below

Not currently logged in
Email:
Password:

Rigel

This page shows the latest Rigel news and features for those working in and with pharma, biotech and healthcare.

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... We look forward to working with Rigel to advance its clinical development,” he added.

Latest news

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    The FDA gave the go-ahead to a pair of rare disease therapies this week, both marking the first-ever approvals for developers Rigel Pharmaceuticals and Ultragenyx. ... Rigel is also developing it for additional indications, including autoimmune

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... In August, Rigel reported the same 18

  • BMS buys immunotherapy specialist Flexus in $1.2bn deal BMS buys immunotherapy specialist Flexus in $1.2bn deal

    And signs new cancer research partnership with Rigel. Bristol-Myers Squibb will spend big to buy out Flexus Biosciences, a privately-held biotech focused on developing new anti-cancer therapeutics. ... Meanwhile, this announcement was made on the same

  • Rigel plans job cuts in R&D restructure Rigel plans job cuts in R&D restructure

    The majority of the positions to be eliminated will be in drug discovery, with Rigel looking to focus its pipeline on three lead programmes in relatively late-stage development. ... Rigel said it expects to advance one of these two molecules into a phase

  • Rigel on the slide as asthma drug falls over Rigel on the slide as asthma drug falls over

    Share plummet after phase II failure of R343. Shares in US pharma company Rigel took a nosedive yesterday after an asthma drug in development at the company failed a phase II ... This was not the result we expected based on the collection of data we had

More from news
Approximately 5 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Pharma deals in February 2015 Pharma deals in February 2015

    February saw BMS further signal its intention to lead in this space announcing two simultaneous deals, the acquisition of Flexus Biosciences and a collaboration with Rigel. ... The earlier stage collaborative deal with Rigel is to develop and

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - develop and commercialise. 342. Rigel Pharmaceuticals/ BMS. Small molecule TGF beta receptor kinase inhibitors - immuno-oncology.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....